ID   M4K2_HUMAN              Reviewed;         820 AA.
AC   Q12851; Q86VU3;
DT   28-FEB-2003, integrated into UniProtKB/Swiss-Prot.
DT   25-NOV-2008, sequence version 2.
DT   12-OCT-2022, entry version 201.
DE   RecName: Full=Mitogen-activated protein kinase kinase kinase kinase 2;
DE            EC=2.7.11.1;
DE   AltName: Full=B lymphocyte serine/threonine-protein kinase;
DE   AltName: Full=Germinal center kinase;
DE            Short=GC kinase;
DE   AltName: Full=MAPK/ERK kinase kinase kinase 2;
DE            Short=MEK kinase kinase 2;
DE            Short=MEKKK 2;
DE   AltName: Full=Rab8-interacting protein;
GN   Name=MAP4K2; Synonyms=GCK, RAB8IP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000312|EMBL:AAA20968.1};
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2-820 (ISOFORM 1), FUNCTION, DOMAIN, AND
RP   TISSUE SPECIFICITY.
RC   TISSUE=Tonsil;
RX   PubMed=7515885; DOI=10.1016/s0021-9258(19)89463-2;
RA   Katz P., Whalen G., Kehrl J.H.;
RT   "Differential expression of a novel protein kinase in human B lymphocytes.
RT   Preferential localization in the germinal center.";
RL   J. Biol. Chem. 269:16802-16809(1994).
RN   [5]
RP   FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=7477268; DOI=10.1038/377750a0;
RA   Pombo C.M., Kehrl J.H., Sanchez I., Katz P., Avruch J., Zon L.I.,
RA   Woodgett J.R., Force T., Kyriakis J.M.;
RT   "Activation of the SAPK pathway by the human STE20 homologue germinal
RT   centre kinase.";
RL   Nature 377:750-754(1995).
RN   [6]
RP   FUNCTION, AUTOPHOSPHORYLATION, AND INTERACTION WITH MAP3K1/MEKK1 AND TRAF2.
RX   PubMed=9712898; DOI=10.1074/jbc.273.35.22681;
RA   Yuasa T., Ohno S., Kehrl J.H., Kyriakis J.M.;
RT   "Tumor necrosis factor signaling to stress-activated protein kinase
RT   (SAPK)/Jun NH2-terminal kinase (JNK) and p38. Germinal center kinase
RT   couples TRAF2 to mitogen-activated protein kinase/ERK kinase kinase 1 and
RT   SAPK while receptor interacting protein associates with a mitogen-activated
RT   protein kinase kinase kinase upstream of MKK6 and p38.";
RL   J. Biol. Chem. 273:22681-22692(1998).
RN   [7] {ECO:0000305}
RP   FUNCTION, AND INTERACTION WITH TRAF2 AND MAP3K1.
RX   PubMed=11784851; DOI=10.1128/mcb.22.3.737-749.2002;
RA   Chadee D.N., Yuasa T., Kyriakis J.M.;
RT   "Direct activation of mitogen-activated protein kinase kinase kinase MEKK1
RT   by the Ste20p homologue GCK and the adapter protein TRAF2.";
RL   Mol. Cell. Biol. 22:737-749(2002).
RN   [8]
RP   ACTIVITY REGULATION, FUNCTION, UBIQUITINATION, AND INTERACTION WITH TRAF6.
RX   PubMed=15456887; DOI=10.1128/mcb.24.20.9165-9175.2004;
RA   Zhong J., Kyriakis J.M.;
RT   "Germinal center kinase is required for optimal Jun N-terminal kinase
RT   activation by Toll-like receptor agonists and is regulated by the ubiquitin
RT   proteasome system and agonist-induced, TRAF6-dependent stabilization.";
RL   Mol. Cell. Biol. 24:9165-9175(2004).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH MAP3K11/MLK3.
RX   PubMed=17584736; DOI=10.1074/jbc.m703422200;
RA   Zhong J., Kyriakis J.M.;
RT   "Dissection of a signaling pathway by which pathogen-associated molecular
RT   patterns recruit the JNK and p38 MAPKs and trigger cytokine release.";
RL   J. Biol. Chem. 282:24246-24254(2007).
RN   [10]
RP   REVIEW ON FUNCTION.
RX   PubMed=10026130; DOI=10.1074/jbc.274.9.5259;
RA   Kyriakis J.M.;
RT   "Signaling by the germinal center kinase family of protein kinases.";
RL   J. Biol. Chem. 274:5259-5262(1999).
RN   [11]
RP   REVIEW ON FUNCTION.
RX   PubMed=11316611; DOI=10.1016/s0962-8924(01)01980-8;
RA   Dan I., Watanabe N.M., Kusumi A.;
RT   "The Ste20 group kinases as regulators of MAP kinase cascades.";
RL   Trends Cell Biol. 11:220-230(2001).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-394, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-394, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-394, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-328 AND SER-394, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   -!- FUNCTION: Serine/threonine-protein kinase which acts as an essential
CC       component of the MAP kinase signal transduction pathway. Acts as a MAPK
CC       kinase kinase kinase (MAP4K) and is an upstream activator of the
CC       stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK)
CC       signaling pathway and to a lesser extent of the p38 MAPKs signaling
CC       pathway. Required for the efficient activation of JNKs by TRAF6-
CC       dependent stimuli, including pathogen-associated molecular patterns
CC       (PAMPs) such as polyinosine-polycytidine (poly(IC)),
CC       lipopolysaccharides (LPS), lipid A, peptidoglycan (PGN), or bacterial
CC       flagellin. To a lesser degree, IL-1 and engagement of CD40 also
CC       stimulate MAP4K2-mediated JNKs activation. The requirement for
CC       MAP4K2/GCK is most pronounced for LPS signaling, and extends to LPS
CC       stimulation of c-Jun phosphorylation and induction of IL-8. Enhances
CC       MAP3K1 oligomerization, which may relieve N-terminal mediated MAP3K1
CC       autoinhibition and lead to activation following autophosphorylation.
CC       Mediates also the SAP/JNK signaling pathway and the p38 MAPKs signaling
CC       pathway through activation of the MAP3Ks MAP3K10/MLK2 and MAP3K11/MLK3.
CC       May play a role in the regulation of vesicle targeting or fusion.
CC       regulation of vesicle targeting or fusion.
CC       {ECO:0000269|PubMed:11784851, ECO:0000269|PubMed:15456887,
CC       ECO:0000269|PubMed:17584736, ECO:0000269|PubMed:7477268,
CC       ECO:0000269|PubMed:7515885, ECO:0000269|PubMed:9712898}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:7515885};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:7515885};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:7515885};
CC   -!- ACTIVITY REGULATION: The tumor necrosis factor (TNF), as well as
CC       endotoxins and pro-inflammatory stimuli such as polyinosine-
CC       polycytidine (poly(IC)), lipopolysaccharides (LPS), peptidoglycan
CC       (PGN), flagellin, or lipid A activate MAP4K2 by promoting its
CC       autophosphorylation. {ECO:0000269|PubMed:15456887,
CC       ECO:0000269|PubMed:7477268}.
CC   -!- SUBUNIT: Interacts with TRAF2, TRAF6, MAP3K1/MEKK1 and MAP3K11/MLK3.
CC       Interacts with RAB8A (By similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       Q12851; Q13233: MAP3K1; NbExp=2; IntAct=EBI-49783, EBI-49776;
CC       Q12851; Q9NUX5: POT1; NbExp=2; IntAct=EBI-49783, EBI-752420;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Basolateral cell
CC       membrane {ECO:0000250}; Peripheral membrane protein {ECO:0000250}.
CC       Golgi apparatus membrane {ECO:0000250}; Peripheral membrane protein
CC       {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q12851-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q12851-2; Sequence=VSP_054134;
CC   -!- TISSUE SPECIFICITY: Highly expressed in germinal center but not mantle
CC       zone B-cells. Also expressed in lung, brain and placenta and at lower
CC       levels in other tissues examined. {ECO:0000269|PubMed:7515885}.
CC   -!- DOMAIN: The PEST domains are Pro-, Glu-, Ser-, and Thr-rich domains.
CC       Proteins with PEST domains are frequently targets of degradation by the
CC       ubiquitin proteasome. {ECO:0000269|PubMed:7515885}.
CC   -!- PTM: Polyubiquitinated through 'Lys-48'-polyubiquitin chains, allowing
CC       proteasomal turnover. Ubiquitination requires the kinase activity of
CC       MAP4K2/GCK. {ECO:0000269|PubMed:15456887}.
CC   -!- PTM: Autophosphorylated in response to tumor necrosis factor (TNF),
CC       endotoxins or pro-inflammatory stimuli. Autophosphorylation leads to
CC       activation.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. STE20 subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA20968.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AP001462; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471076; EAW74302.1; -; Genomic_DNA.
DR   EMBL; BC047865; AAH47865.1; -; mRNA.
DR   EMBL; U07349; AAA20968.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS8082.1; -. [Q12851-1]
DR   CCDS; CCDS81582.1; -. [Q12851-2]
DR   PIR; A53714; A53714.
DR   RefSeq; NP_001294919.1; NM_001307990.1. [Q12851-2]
DR   RefSeq; NP_004570.2; NM_004579.4. [Q12851-1]
DR   AlphaFoldDB; Q12851; -.
DR   SMR; Q12851; -.
DR   BioGRID; 111809; 93.
DR   IntAct; Q12851; 17.
DR   MINT; Q12851; -.
DR   STRING; 9606.ENSP00000294066; -.
DR   BindingDB; Q12851; -.
DR   ChEMBL; CHEMBL5330; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q12851; -.
DR   GuidetoPHARMACOLOGY; 2086; -.
DR   iPTMnet; Q12851; -.
DR   PhosphoSitePlus; Q12851; -.
DR   BioMuta; MAP4K2; -.
DR   DMDM; 215274019; -.
DR   CPTAC; CPTAC-862; -.
DR   CPTAC; CPTAC-863; -.
DR   EPD; Q12851; -.
DR   jPOST; Q12851; -.
DR   MassIVE; Q12851; -.
DR   MaxQB; Q12851; -.
DR   PaxDb; Q12851; -.
DR   PeptideAtlas; Q12851; -.
DR   PRIDE; Q12851; -.
DR   ProteomicsDB; 58984; -. [Q12851-1]
DR   ProteomicsDB; 70069; -.
DR   Antibodypedia; 2060; 249 antibodies from 27 providers.
DR   DNASU; 5871; -.
DR   Ensembl; ENST00000294066.7; ENSP00000294066.2; ENSG00000168067.12. [Q12851-1]
DR   Ensembl; ENST00000377350.7; ENSP00000366567.3; ENSG00000168067.12. [Q12851-2]
DR   GeneID; 5871; -.
DR   KEGG; hsa:5871; -.
DR   MANE-Select; ENST00000294066.7; ENSP00000294066.2; NM_004579.5; NP_004570.2.
DR   UCSC; uc001obh.4; human. [Q12851-1]
DR   CTD; 5871; -.
DR   DisGeNET; 5871; -.
DR   GeneCards; MAP4K2; -.
DR   HGNC; HGNC:6864; MAP4K2.
DR   HPA; ENSG00000168067; Low tissue specificity.
DR   MIM; 603166; gene.
DR   neXtProt; NX_Q12851; -.
DR   OpenTargets; ENSG00000168067; -.
DR   PharmGKB; PA30610; -.
DR   VEuPathDB; HostDB:ENSG00000168067; -.
DR   eggNOG; KOG0576; Eukaryota.
DR   GeneTree; ENSGT00940000162250; -.
DR   InParanoid; Q12851; -.
DR   OMA; DTANNPE; -.
DR   OrthoDB; 996262at2759; -.
DR   PhylomeDB; Q12851; -.
DR   TreeFam; TF105121; -.
DR   PathwayCommons; Q12851; -.
DR   SignaLink; Q12851; -.
DR   SIGNOR; Q12851; -.
DR   BioGRID-ORCS; 5871; 31 hits in 1083 CRISPR screens.
DR   GeneWiki; MAP4K2; -.
DR   GenomeRNAi; 5871; -.
DR   Pharos; Q12851; Tchem.
DR   PRO; PR:Q12851; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q12851; protein.
DR   Bgee; ENSG00000168067; Expressed in granulocyte and 116 other tissues.
DR   ExpressionAtlas; Q12851; baseline and differential.
DR   Genevisible; Q12851; HS.
DR   GO; GO:0016323; C:basolateral plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0000139; C:Golgi membrane; TAS:ProtInc.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0008349; F:MAP kinase kinase kinase kinase activity; IBA:GO_Central.
DR   GO; GO:0031435; F:mitogen-activated protein kinase kinase kinase binding; IPI:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0006955; P:immune response; TAS:ProtInc.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB.
DR   GO; GO:0007254; P:JNK cascade; TAS:ProtInc.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IDA:UniProtKB.
DR   GO; GO:0043507; P:positive regulation of JUN kinase activity; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0006903; P:vesicle targeting; IEA:Ensembl.
DR   InterPro; IPR001180; CNH_dom.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR021160; MAPKKKK.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   Pfam; PF00780; CNH; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   PIRSF; PIRSF038172; MAPKKKK; 1.
DR   SMART; SM00036; CNH; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50219; CNH; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cell membrane; Cytoplasm;
KW   Golgi apparatus; Immunity; Innate immunity; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Stress response; Transferase;
KW   Ubl conjugation.
FT   CHAIN           1..820
FT                   /note="Mitogen-activated protein kinase kinase kinase
FT                   kinase 2"
FT                   /id="PRO_0000086275"
FT   DOMAIN          16..273
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          482..793
FT                   /note="CNH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00795"
FT   REGION          294..314
FT                   /note="PEST1"
FT   REGION          344..360
FT                   /note="PEST2"
FT   REGION          387..442
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          405..448
FT                   /note="PEST3"
FT   COMPBIAS        409..438
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        136
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         22..30
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         45
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         328
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         394
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         426..433
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_054134"
FT   CONFLICT        120
FT                   /note="A -> R (in Ref. 4; AAA20968)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   820 AA;  91556 MW;  A59C1E99BFFAEF41 CRC64;
     MALLRDVSLQ DPRDRFELLQ RVGAGTYGDV YKARDTVTSE LAAVKIVKLD PGDDISSLQQ
     EITILRECRH PNVVAYIGSY LRNDRLWICM EFCGGGSLQE IYHATGPLEE RQIAYVCREA
     LKGLHHLHSQ GKIHRDIKGA NLLLTLQGDV KLADFGVSGE LTASVAKRRS FIGTPYWMAP
     EVAAVERKGG YNELCDVWAL GITAIELGEL QPPLFHLHPM RALMLMSKSS FQPPKLRDKT
     RWTQNFHHFL KLALTKNPKK RPTAEKLLQH PFTTQQLPRA LLTQLLDKAS DPHLGTPSPE
     DCELETYDMF PDTIHSRGQH GPAERTPSEI QFHQVKFGAP RRKETDPLNE PWEEEWTLLG
     KEELSGSLLQ SVQEALEERS LTIRSASEFQ ELDSPDDTMG TIKRAPFLGP LPTDPPAEEP
     LSSPPGTLPP PPSGPNSSPL LPTAWATMKQ REDPERSSCH GLPPTPKVHM GACFSKVFNG
     CPLRIHAAVT WIHPVTRDQF LVVGAEEGIY TLNLHELHED TLEKLISHRC SWLYCVNNVL
     LSLSGKSTHI WAHDLPGLFE QRRLQQQVPL SIPTNRLTQR IIPRRFALST KIPDTKGCLQ
     CRVVRNPYTG ATFLLAALPT SLLLLQWYEP LQKFLLLKNF SSPLPSPAGM LEPLVLDGKE
     LPQVCVGAEG PEGPGCRVLF HVLPLEAGLT PDILIPPEGI PGSAQQVIQV DRDTILVSFE
     RCVRIVNMQG EPTATLAPEL TFDFPIETVV CLQDSVLAFW SHGMQGRSLD TNEVTQEITD
     ETRIFRVLGA HRDIILESIP TDNPEAHSNL YILTGHQSTY
//
